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ABSTRACT 
 
Magnesium sulphate is a potential treatment for acute severe asthma. However, 
the mechanisms and dose-response relationships are poorly understood. The 
first objective of this study was to examine whether inhaled magnesium sulphate 
exerts bronchodilator activity measured as bronchoprotection against histamine-
induced bronchoconstriction in conscious guinea-pigs alone and combined with 
salbutamol. Secondly, we examined whether inhaled magnesium sulphate 
inhibits airways inflammation and function in models of neutrophilic and 
eosinophilic lung inflammation induced, respectively, by inhaled 
lipopolysaccharide or the inhaled antigen, ovalbumin (OVA). Airway function was 
measured in conscious guinea-pigs as specific airway conductance (sGaw) by 
whole-body plethysmography. Anti-inflammatory activity was measured against 
lung inflammatory cell influx induced by OVA inhalation in OVA-sensitised 
animals or by lipopolysaccharide (LPS) exposure of non-sensitised animals.  
Airway function (sGaw) was measured over 24 h after OVA exposure. Airway 
hyperresponsiveness to inhaled histamine and inflammatory cells in 
bronchoalveolar lavage fluid were recorded 24 h after OVA or LPS challenge. 
Histamine-induced bronchoconstriction was inhibited by inhaled magnesium 
sulphate or salbutamol alone and in combination, they produced synergistic 
bronchoprotection. LPS-induced neutrophil influx was inhibited by 6 days 
pretreatment with magnesium sulphate. Early and late asthmatic responses in 
OVA sensitized and challenged animals were attenuated by magnesium 
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sulphate. Lung inflammatory cells were increased by OVA, macrophages being 
significantly reduced by magnesium sulphate. Nebulised magnesium sulphate 
protects against histamine-induced bronchoconstriction in conscious guinea-pigs 
and exerts anti-inflammatory activity against pulmonary inflammation induced by 
allergen (OVA) or LPS. These properties of magnesium sulphate explain its 
beneficial actions in acute asthma. (246 words) 
 
Key words 
Magnesium sulphate; asthma; bronchoprotection; guinea-pigs; airways 
inflammation; lipopolysaccharide 
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1. Introduction 
The use of magnesium sulphate (MgSO4) for acute asthma was first described in 
1936, and since then there has been inconsistent evidence to support its use in 
adults and children with asthma (Mohammed and Goodacre, 2007). Recent 
systematic reviews have suggested that both inhaled and intravenous MgSO4 
has a potential role in patients with a more severe exacerbation of acute asthma 
(Mohammed and Goodacre, 2007; Powell et al., 2012).  However, the exact role 
of MgSO4 is not fully delineated (Rowe, 2013).   A large randomized controlled 
trial of nebulised MgSO4 with 508 children with severe acute asthma has shown 
a minimal effect on asthma severity scores but in those children with a more 
severe exacerbation and those with shorter duration of symptoms the effect 
appeared to be more clinically relevant (Powell et al., 2013).  A randomised 
controlled trial with 1109 adult patients, has shown no significant clinical benefit 
from the addition of nebulised MgSO4 to standard treatment in acute asthma, 
although a minimal benefit was shown in severe asthma when given 
intravenously (Goodacre et al., 2013).  
 
The exact mechanism of action of MgSO4 in asthma is not understood. It 
appears to have some bronchodilator or bronchoprotective effects for which there 
are a number of proposed mechanisms. In vitro studies demonstrate an inhibitory 
effect of MgSO4 on contraction of bronchial smooth muscle, the release of 
acetylcholine from cholinergic nerve terminals, and of histamine from mast cells 
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(Blitz et al., 2005). The main effect of MgSO4 is to block the influx of calcium ions 
into smooth muscle cells of the airways (Georgoulianis et al., 2001) which results 
in bronchodilatation. One previous study demonstrates bronchoprotective effects 
of magnesium fluoride and MgSO4 against inhaled methacholine in rats (Gandia 
et al., 2010), although Lindeman et al. (1985) failed to show any effect of 
intravenous MgSO4 against acetylcholine-induced bronchoconstriction in 
anaesthetized dogs. There is evidence that MgSO4 may also act as an anti-
inflammatory agent by inhibiting the neutrophil respiratory burst in adults with 
asthma (Cairns and Kraft, 1996). 
 
This study was undertaken to explore the actions of nebulised MgSO4 in the 
airways of conscious guinea-pigs. There were two main objectives: Firstly, we 
examined whether inhaled magnesium sulphate exerts bronchodilator activity by 
measuring whether it has bronchoprotective properties against histamine-
induced bronchoconstriction. We examined the speed of onset and dose-
response relationships. Magnesium sulphate was examined on the airways 
function responses to inhaled histamine either alone or in combination with the 
β2-adrenoceptor agonist, salbutamol. Secondly, we examined the hypothesis that 
inhaled magnesium sulphate inhibits airways inflammation and airways function 
in models of neutrophilic and eosinophilic lung inflammation. Neutrophilic 
inflammation was induced by inhaled lipopolysaccharide. Eosinophilic 
inflammation and the accompanying early and late asthmatic responses and 
airways hyperresponsiveness were induced by the inhaled antigen, ovalbumin, in 
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ovalbumin-sensitised animals. 
 
2. Materials and methods  
 
2.1. Guinea-pig airways function and inflammation models 
Naïve conscious guinea-pigs challenged with nebulised histamine exhibit an 
immediate bronchoconstrictor response that recovers to baseline within 10 min. 
Immediate bronchodilator effects of agents such as magnesium sulphate can be 
measured as a reduced bronchoconstriction by inhaled histamine when 
administered immediately before the histamine; this is known as 
bronchoprotection (Turner et al., 2012). To examine the effects of a drug such as 
magnesium sulphate against models of asthma and chronic obstructive 
pulmonary disease (COPD) the main features of these lung diseases need to be 
induced. The four main features of asthma, namely airways hyperreactivity or 
hyperesponsiveness (AHR), inflammatory cell influx into the airways 
(predominantly eosinophils) and early (EAR) and late asthmatic responses 
(LAR), can be reproduced in conscious guinea-pigs sensitised and challenged 
with ovalbumin (Toward and Broadley, 2004). Guinea-pigs challenged with 
inhaled lipopolysaccharide (LPS) exhibit neutrophil driven pulmonary 
inflammatory responses similar to COPD (Toward and Broadley, 2000). 
Magnesium sulphate was administered as a single dose prior to OVA challenge 
or as several doses over a few days before LPS challenge. 
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2.2. Animal husbandry 
Groups of six male Dunkin-Hartley guinea-pigs (200-250 g) were obtained from 
Charles River, Sulzfeld, Germany and housed in solid bottomed cages. A total of 
96 animals were used. Light was maintained on a 12 h cycle and food and water 
were available ad libitum. All experiments complied with the Animals (Scientific 
Procedures) Act, 1986 and protocols were reviewed by Cardiff University Ethical 
Review Panel. The ARRIVE Guidelines on Animal Research: Reporting In Vivo 
Experiments have been adhered to in the design and execution of the study 
(Kilkenny et al., 2012; McGrath et al., 2010). 
 
2.3. Measurement of lung function 
Airways function was measured by whole-body plethysmography as specific 
airway conductance (sGaw) in conscious guinea-pigs using a non-invasive 
double-chamber plethysmograph (Buxco Systems, Wilmington, North Carolina, 
USA). Guinea-pigs were placed in the double chamber plethysmograph and 
restrained by use of a neck restraint which also separated the nasal and thoracic 
compartments of the chamber making them both airtight. Air temperature and 
gas percentages were kept constant by use of a bias flow supply unit. Box 
pressure changes in both compartments were measured by pressure 
transducers. The pre-amplified output was converted to inspiratory and expiratory 
waveforms by Finepoint software (Buxco system Ltd), which also derives sGaw. 
Readings were taken every 2 s and at least 20 breaths were recorded during any 
time point measurement. For calculation of sGaw at a particular time point, the 
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average of 15 values taken at random was calculated. 
Prior to the commencement of lung function measurements, all guinea-pigs were 
acclimatised to being restrained in the plethysmograph for at least 20 min on two 
separate occasions. This reduces movement-related signal ‘noise’ during 
measurements and reduces animal stress minimising interference from stress-
related hormones such as cortisol. A decrease in sGaw represents 
bronchoconstriction while an increase is a bronchodilator response.  
 
2.4. Bronchoprotection by nebulised MgSO4 and salbutamol 
Baseline sGaw readings were determined before challenge of naïve unsensitised 
guinea-pigs. With them still in the plethysmograph, they were challenged with 
nebulised histamine (0.5 mM solution for 2 min) delivered by use of a Buxco 
nebuliser at 0.5 l/min and 20% duty (% every 6 s of nebulising) per chamber. 
sGaw was measured immediately after completing the challenge and at 5 and 10 
min. After forty-eight hours, the same animals were treated with inhaled MgSO4, 
salbutamol or vehicle (0.9% saline) and the histamine challenge repeated 15 min 
after completion of the drug or vehicle exposure. Lung function was then re-
assessed as above. Each animal received one challenge with MgSO4, 
salbutamol or vehicle in any one week. 
 
Administration of nebulised MgSO4 (62.5-250 mM), salbutamol (0.035-0.1 mM), 
vehicle (0.9% saline) or a combination of MgSO4 and salbutamol was achieved 
with a DeVilbiss nebulizer (Somerset, Pennsylvania, USA) by placing the guinea-
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pigs in an in-house Perspex chamber (20x30x15 cm) for 15min. 
 
2.5. Effect of nebulised MgSO4 on an ovalbumin model of asthma 
Guinea-pigs were sensitised to ovalbumin on days 1, 4 and 7 by bi-lateral intra-
peritoneal injection of ovalbumin (100 µg) and aluminium hydroxide (150 mg) 
suspended in saline (1 ml). On day 19, baseline sGaw values were determined 
before placing the guinea-pigs into the Perspex exposure chamber for challenge 
with nebulised ovalbumin (0.03%) for 1 h using a DeVilbiss nebuliser. Guinea-
pigs were removed from the chamber and sGaw was measured every 15 min for 
the first hour following ovalbumin challenge and every hour thereafter for 12 h. A 
further reading was taken 24 h after the ovalbumin challenge. sGaw was 
expressed as the percentage change from baseline. Animals were treated with 
nebulised MgSO4 (250 mM) or vehicle for 15 min before ovalbumin challenge. 
 
2.6. Effect of nebulised MgSO4 on LPS-induced inflammation 
Naïve unsensitised guinea-pigs were exposed daily to nebulised saline or MgSO4 
(250 mM) for 15 min in the Perspex exposure chamber (30x40x30 cm) on days 1 
to 6. On day 4, 30 min after treatment with saline or MgSO4, animals were 
exposed to a priming challenge with nebulised LPS (30 µg/ml) for 1 h. On day 6 
they received a second identical challenge with LPS 30 min after saline or 
MgSO4 and 24 h later, bronchoalveolar lavage was performed to determine 
inflammatory cell influx into the airways.  
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2.7. Airway responsiveness to inhaled histamine 
Airway reactivity to a dose of inhaled histamine (0.3 mM) that produced non-
significant threshold bronchoconstriction was evaluated 24 h before and 24 h 
after ovalbumin challenge. Baseline sGaw values were determined before 0.3 mM 
histamine was delivered via inhalation (2 min at 20% duty) and sGaw was 
measured immediately and at 5 and 10 min.  
 
2.8. Bronchoalveolar lavage and inflammatory cell counts 
After the final histamine challenge of the ovalbumin experiments or 24 h after the 
second LPS exposure, guinea-pigs were euthetized with an overdose of sodium 
pentobarbitone (Euthetal, 400 mg/kg i.p.). The trachea was cannulated and the 
lungs removed before instilling the left lung with saline (1 ml per 100 g body 
weight) for 3 min before withdrawal. This was repeated and the samples pooled 
for counting the total number of cells/ml with a Neubauer haemocytometer 
(Sigma-Aldrich, Gillingham, Dorset, UK). Differential counts of eosinophils, 
macrophages, lymphocytes and neutrophils were performed after centrifuging 
100 µl of lavage fluid onto a glass microscope slide using a Shandon Cytospin 
centrifuge (ThermoFisher Scientific, Hemel Hempstead, UK) at 110 x g for 7 min. 
Slides were then stained with 1.5% Leishman’s solution in 100% methanol for 6 
min. A minimum of 200 cells were counted. 
 
2.9. Calculation of responses 
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sGaw values were determined at baseline before histamine or ovalbumin 
inhalation and at each time point after exposure. The percentage change from 
baseline was calculated. The peak fall in sGaw in response to histamine was then 
determined for each animal. The percentage changes in sGaw values for 
histamine after inhalation of MgSO4, salbutamol or their combination were then 
expressed as a percentage of the pre-treatment peak fall in sGaw. The mean 
percentage inhibitions of the histamine responses were then plotted against 
molar concentrations and the potency-ratio calculated at the IC50. All data is 
presented as the mean ± standard error of the mean (S.E.M.). Because the time 
of peak fall in sGaw occurring during the late asthmatic response following 
ovalbumin inhalation varied between animals, only the peak fall in sGaw between 
9 and 11 h was plotted. 
 
2.10. Statistical analysis   
Student’s paired t-test was used to determine significance of inhibitory effects on 
the histamine-induced bronchoconstriction, from the pre- and post-drug 
responses to histamine. One-way analysis of variance (ANOVA), followed by 
post-hoc Tukey’s or Dunnett’s test was used to determine significant differences 
between different treatment groups. Significance was determined as P<0.05. 
 
2.11. Drugs 
Magnesium sulphate was provided as isotonic MgSO4 (250 mmol/l, tonicity 289 
milliosmole; 151 mg per dose manufactured by St Mary’s Pharmaceutical Unit, 
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Cardiff, UK). The dose range of MgSO4 was selected to equate with clinical 
experience in which 250 mM has been used in children with acute asthma 
(Powell et al., 2013). Aluminium hydroxide, histamine diphosphate, ovalbumin 
and salbutamol hemisulphate were obtained from Sigma-Aldrich, Gillingham, 
Dorset, UK. Sodium pentobarbitone (Euthetal) was purchased from Merial, 
Harlow, UK. Drugs and materials were dissolved in saline purchased from Baxter 
Healthcare, Newbury, UK. 
 
3. Results 
3.1. Bronchoprotection by nebulised MgSO4 and salbutamol 
Bronchoprotection was measured as a reduction of histamine-induced 
bronchoconstriction. Histamine (0.5 mM) induced a significant fall in sGaw in 
conscious guinea-pigs, indicating a substantial bronchoconstriction that 
recovered to baseline 10 min post-challenge. Guinea-pigs treated 48 h later with 
the saline vehicle 15 min prior to the histamine challenge also demonstrated a 
significant bronchoconstriction to histamine, which was not significantly different 
from the response before saline (7.9+10.7% inhibition) (Fig. 1A). Nebulised 
MgSO4 dose-dependently inhibited the histamine response over the dose range 
of 62.5-250 mM, inhibiting by 23.4+6.5% at 62.5 mM, and 46.8+5.6% and 
85.4+18.1% at 125 and 250 mM, respectively (Fig. 1A). Inhibition of the 
histamine response was significant at 250 mM (P<0.01).  
 
Nebulised salbutamol caused dose-dependent inhibition of histamine-induced 
bronchoconstriction over the dose range of 0.035 - 0.1 mM, inhibiting the 
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histamine response at 0.035 mM by 21.8+13.2% and increasing to 90.6+11.2% 
at 0.1 mM (Fig. 1B). The dose-response curves (Fig. 1C) showed that salbutamol 
was more potent than MgSO4 with a potency-ratio of 2049 at the IC50.  
 
Co-administration of salbutamol (0.035 mM) and MgSO4 (62.5 mM), which alone 
had no significant inhibitory effects, significantly inhibited histamine-induced 
bronchoconstriction by 104.7+16.6% (Fig. 1D). It is possible to achieve more 
than 100% inhibition because sGaw may fall below baseline after the second 
exposure to histamine. To determine whether this was a synergistic effect, where 
the effect of the two bronchodilators together is greater than the sum of their 
individual effects, we applied the principles described by Tallarida (Tallarida et 
al., 1999; Tallarida, 2001). From the potency-ratio (R) between salbutamol and 
MgSO4 (2049), the dose (Aeq) of MgSO4 to yield the same response as the 
combination can be calculated from the equation Aeq = a + bR, where a = dose of 
MgSO4 and b = dose of salbutamol in the combination. This yielded a value of 
Aeq of 134.2 mM. The dose-response curve for MgSO4 alone shows that the 
actual response to the combination (104.7+16.6%) would be generated by a 
corresponding dose (Acorr) of 400mM of MgSO4. The interaction index  is the 
ratio Aeq/Acorr = 0.33. This value is less than unity and therefore indicates that a 
synergistic interaction has occurred between MgSO4 and salbutamol.   
 
3.2. Effects of nebulised MgSO4 on ovalbumin-induced changes in lung 
function, airway reactivity and inflammatory cell influx 
 
3.2.1. Lung function – early and late asthmatic responses Exposure of sensitised 
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guinea-pigs to inhaled ovalbumin elicited an immediate fall in sGaw of -65.8±3.8% 
(n=6). This bronchoconstriction was the early asthmatic response (EAR), which 
returned to baseline after 5 h. A second fall in sGaw of -34.7+14.1% was 
observed between 7-12 h. This bronchoconstriction was the late asthmatic 
response (LAR) which returned to baseline 12 h after the ovalbumin challenge. 
 
Guinea-pigs sensitised and challenged with ovalbumin but pre-treated with 
vehicle (0.9% saline) exhibited an EAR, the peak nadir change in sGaw being       
-64.1+4.3%. A second fall in sGaw occurred between 9 and 11 h, the mean peak 
being -20.5+5.7% (Fig. 2).  This was not significantly different from the ovalbumin 
alone group.  Animals treated with a single dose of nebulised MgSO4 30 min 
before ovalbumin challenge had a significantly reduced EAR compared to the 
vehicle group with a peak fall in sGaw of -32.3+9.3%, which was significantly less 
than the vehicle group (Fig. 2). The mean peak LAR between 9 and 11 h (-
3.7+2.0%) was also significantly attenuated in MgSO4-treated guinea-pigs (Fig. 
2). 
 
3.2.2. Lung function - airway hyperreactivity to histamine Guinea-pigs did not 
demonstrate a bronchoconstriction to the low dose (0.3 mM) of histamine prior to 
the ovalbumin challenge (Fig. 3). However, 24 h after the ovalbumin challenge, in 
animals receiving no treatment or those receiving inhaled vehicle, there were 
immediate, significant falls in sGaw of -27.4+1.7% and -33.8+6.5%, respectively, 
after histamine exposure. This response was diminished in guinea-pigs treated 
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with MgSO4, with a non-significant change in sGaw of -11.5+6.4% at zero time 
(Fig. 3). MgSO4 treatment appeared to alter the shape of the histamine response 
which was now delayed with a small significant fall in sGaw at 10 min. 
 
3.2.3. Airway inflammation Ovalbumin-sensitised and challenged animals had a 
significant influx of total inflammatory cells into the airway (10.7+0.5x106/ml), 
compared with naïve animals (Fig. 4). This increase in inflammatory cells was 
predominantly associated with an influx of eosinophils (4.4+0.5x106/ml) and 
macrophages (4.3+0.3x106/ml), although lymphocytes (0.4+0.06x106/ml) and 
neutrophils (0.9+0.2x106/ml) were also evident (Fig. 4).  
 
Vehicle-treated OVA challenged animals also demonstrated an increased 
number of total cells in the airways (9.2+1.3x106/ml) and these together with 
individual cell types were not significantly different from OVA challenged animals 
without vehicle. MgSO4 treatment did not significantly reduce total cells 
(8.4+0.9x106/ml), eosinophils (5.32+0.8x106/ml), lymphocytes (0.51+0.08x106/ml) 
or neutrophils (0.66+0.17x106/ml). However, macrophages were significantly 
lower in the MgSO4-treatment group (1.9+0.2x106/ml) than the vehicle group 
(2.90+0.53x106/ml) (Fig. 4). 
 
3.3. Effect of nebulised MgSO4 on LPS-induced inflammation 
Guinea-pigs exposed to LPS had significantly more total cells in their airways 
than naïve animals (24.4+1.3x106/ml and 1.5+0.2x106/ml, respectively) (Fig. 5). 
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This increase was predominantly a result of neutrophil influx (15.2+0.7x106/ml, 
compared to 0.035+0.005x106/ml-1 in naïve animals). Eosinophils and 
lymphocytes were also increased in LPS-treated animals compared to naïve 
animals. 
 
Animals treated with saline vehicle had a significant increase in total cell counts 
(23.5+2.0x106/ml) (Fig. 5), which were not significantly different from untreated 
LPS-challenged animals. MgSO4 significantly reduced the total cells to 
16.8+1.4x106/ml (Fig. 5). Macrophages, lymphocytes and eosinophils were not 
different between vehicle- and MgSO4-treated animals. However, a significant 
reduction in neutrophils was observed following treatment with MgSO4 
(8.1+0.6x106/ml) compared to vehicle (16.3+1.5x106/ml) (Fig. 5). 
 
4. Discussion 
 
These studies have demonstrated for the first time the actions of nebulised 
magnesium sulphate on airways function and inflammation in conscious guinea-
pigs and indeed in any laboratory species. Our results clarify the clinical 
application of inhaled MgSO4 in the treatment of acute asthma in children.    
 
Firstly, we have shown that inhaled MgSO4 causes a dose-dependent 
bronchoprotection against histamine-induced bronchoconstriction (Fig. 1), which 
can be attributed to a direct bronchodilator action on the airways smooth muscle. 
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This confirms observations that MgSO4 relaxes rabbit isolated tracheal smooth 
muscle (Georgoulianis et al., 2001) and bronchoprotection against methacholine-
induced bronchoconstriction in rats (Gandia et al., 2010). However, Yoshioka et 
al. (2001) and Lindeman et al. (1989) failed to show any inhibition of 
bronchoconstriction to intravenous 5-hydroxytryptamine or inhaled acetylcholine, 
respectively, in anaesthetized dogs. In clinical studies, a number of different 
doses of nebulised MgSO4 have been used (Powell et al., 2012) but we still do 
not know the appropriate dose nor indeed the frequency of nebulised MgSO4 to 
achieve a maximal response in either adults or children. From our results, it 
would appear that the 250 mM dose produces optimum effect and this relates 
directly with the inhaled dose used in the MAGNETIC study (Powell et al., 2013). 
We also showed that the short-acting -adrenoceptor agonist, salbutamol, 
caused dose-related inhibition of the histamine bronchoconstriction. This 
confirms our previous studies (Turner et al., 2010) and clearly demonstrates the 
ability of this model to display the effectiveness of inhaled bronchodilators such 
as -adrenoceptor agonists. The combination of ineffective doses of MgSO4 and 
salbutamol exerted a significant bronchoprotective effect which our calculations 
showed to be greater than the sum of their individual effects, namely synergism. 
The exact nature of this synergistic interaction is not understood but may 
represent an interaction between magnesium and salbutamol at the -
adrenoceptor. The -adrenoceptor binding sites for agonist binding (i.e. 
salbutamol) are converted to high affinity binding by Mg2+ (Broadley, 1996) and in 
the presence of Mg2+, the affinity of agonist binding to the -adrenoceptor is 
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increased (Cech and Maguire, 1982). An increased agonist binding affinity to the 
-adrenoceptor in the presence of Mg2+ would thus explain the enhanced 
response to salbutamol. It would be interesting to confirm that this is a class 
effect and applies to all β-adrenoceptor agonists. This finding has important 
clinical implication in that co-administration of a -agonist with MgSO4 will allow 
the dose of the agonist to be reduced thereby minimizing any undesirable side 
effects. 
 
Secondly, we examined the effects of MgSO4 in an ovalbumin model of asthma 
which displays three important functional features of the asthmatic airways: the 
early (EAR) and late asthmatic bronchoconstrictor responses (LAR) and airways 
hyperreactivity (AHR). Both the EAR and LAR were significantly reduced after a 
single inhaled dose of MgSO4 (Fig. 2).  Airways hyperreactivity to histamine was 
reduced in those animals pre-exposed to MgSO4 (Fig. 3). The MAGNETIC study 
has suggested that those children with a short duration of symptoms, which 
would equate with the EAR, seem to respond better to MgSO4 (Powell et al., 
2013). Although this needs to be explored further in the clinical situation, the 
marked effect on the early asthmatic response seen in this guinea-pig model 
would support that hypothesis. The inhibition of the LAR and AHR by MgSO4 
administered immediately before the ovalbumin exposure is unlikely to be due to 
its bronchodilator action since this action would have diminished by the time of 
the LAR (9-11 h) and measurement of AHR, 24 h after ovalbumin administration. 
A similar result to the one presented here was protection of guinea-pig hearts 
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against allergen-induced anaphylactic shock by Intraperitoneal magnesium 
chloride (Kusniec et al., 1994). 
 
The LAR and AHR seen in our asthma model after OVA challenge have been 
shown to be closely associated in human asthmatics (Hargreave et al., 1986) and 
in guinea-pig models of asthma (Smith and Broadley, 2007). Both responses to 
OVA are linked to the lung inflammation, in particular the observed increase in 
eosinophils (Bousquet et al., 1990; Laitinen et al., 1996). Pretreatment with 
MgSO4 did not affect eosinophil numbers but significantly reduced numbers of 
macrophages (Fig. 4).  Macrophages can be pro-inflammatory or anti-
inflammatory as there are three different macrophage phenotypes with varying 
functions (Draijer et al., 2013; Mosser and Edwards, 2008; Stout and Suttles, 
2004).  Recent data suggests that macrophages play an important role in the 
development of severe asthma especially steroid-resistant asthma (Yang et al., 
2012).  One subset of macrophages can be a major source of IL-13 production 
which would drive increased mucus production and AHR (Byers and Holtzman, 
2011). Thus, the reduction in macrophage numbers could explain the 
concomitant inhibition of AHR observed after MgSO4 inhalation. It is possible that 
while the dose of MgSO4 used here only affected macrophages, higher doses or 
repeated dosing, for example at 6 h after ovalbumin challenge, may have 
inhibited the other inflammatory cell types. Indeed, in the neutrophilic LPS model, 
which received multiple dosing with MgSO4, there was significant attenuation of 
neutrophil numbers (see below). The LAR is also associated with lung 
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inflammation and it is possible that its inhibition by MgSO4 was due to its anti-
inflammatory activity. In rodents, the LAR may also in part be due to 
parasympathetic reflex activity (Raemdonck et al., 2012) and its inhibition may 
therefore be due to inhibition of this reflex. However, this is unlikely to occur at 
the muscarinic receptor site as others have found that acetylcholine responses 
are not inhibited by MgSO4 (Lindeman et al., 1989). 
 
In contrast to ovalbumin, LPS inhalation caused neutrophil-driven rather than 
eosinophil-driven airways inflammation and is therefore analogous to the 
inflammation associated with chronic obstructive pulmonary disease (COPD). 
This confirms previous observations in guinea-pigs from this (Nevin and 
Broadley, 2004; Toward and Broadley, 2000) and other laboratories Pera et al., 
2011). MgSO4 significantly reduced the neutrophil count in the airways (Fig. 5). 
There is evidence that Mg2+ can exert anti-inflammatory effects against 
neutrophils (Cairns et al., 1996), since the respiratory burst induced by N-formyl-
methionyl-leuyl-phenylalanine (fMLP) in neutrophils isolated from asthmatics was 
reduced by Mg2+, an effect attributed to Mg2+ interfering with the influx of 
extracellular Ca2+. The increase in cytosolic Ca2+ of rat basophilic leukaemia cells 
due to antigen challenge was shown to be reduced by an elevation of Mg2+ in the 
medium (Kusniec et al., 1994). Other inflammatory cells, including T-
lymphocytes, upregulate dihydropyridine-sensitive Ca2+ channels in asthma and 
these control calcium signaling and cytokine production. Dihydropyridine calcium 
antagonists prevent airway inflammation and hyperresponsiveness in 
21 
 
experimental models of asthma (Pelletier and Guéry, 2008). Interference with 
Ca2+ flux may be a common mechanism for the inhibitory actions of MgSO4 seen 
throughout the present study. Ca2+ is involved in the contraction of smooth 
muscle and in the mobilization of inflammatory cells in both the ovalbumin and 
LPS models. Ca2+ has a central role in airway epithelial cells to induce 
proinflammatory gene transcription and the migration of leukocytes (Chun and 
Prince, 2009). Mast cells may be a further site of MgSO4 and Ca2+ interaction, 
since influx of Ca2+ is required for degranulation and release of cytokines (Ma 
and Beaven, 2011). Thus, MgSO4 probably exerts both airways smooth muscle 
relaxation (bronchoprotection) and anti-inflammatory effects through a 
mechanism similar to the calcium antagonists such as nifedipine. Indeed, 
nifedipine and MgSO4 have been shown to blunt hypocapnia- but not 
acetylcholine-induced bronchoconstriction (Lindeman et al., 1989). These 
authors concluded that they preferentially inhibited voltage sensitive calcium 
channels rather than receptor-operated calcium channels. As well as through ion 
channels, Ca2+ modulates cell function via the calcium-sensing receptor (CaSR) 
which is involved in calcium homeostasis. Ca2+ and other divalent cations bind to 
and activate this receptor which is expressed on vascular endothelial cells and 
immune cells, including macrophages (Molostvov et al., 2009). Whether Mg2+ 
activates or inhibits the CaSR is not known, but it remains a likely site of the anti-
inflammatory action of inhaled MgSO4. 
 
Conclusions 
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This study has shown that inhaled MgSO4 exerts a direct immediate 
bronchodilator action in conscious guinea-pig airways, measured as 
bronchoprotection against histamine-induced bronchoconstriction. There was a 
synergistic bronchoprotection between MgSO4 and the β2-adrenoceptor agonist, 
salbutamol. It also exerts a similar bronchoprotection against the immediate 
bronchoconstriction following inhalation of ovalbumin (OVA) in sensitized 
animals, the EAR. A single dose of MgSO4 administered before OVA also 
inhibited the LAR, AHR and inflammatory cell influx. Multiple doses were 
employed against the neutrophilic lung inflammation following LPS challenge and 
were shown to exert anti-inflammatory action against the neutrophil influx. 
The dose-response relationship for MgSO4, the frequency of administration and 
the synergy between MgSO4 and a -adrenoceptor agonist need to be examined 
in humans to identify the ideal dose and timing of administration during an 
exacerbation of acute asthma and further explore whether the two drugs together 
rather than individually has improved outcomes. It will also be necessary to 
examine whether the combination therapy has a synergistic effect upon the 
inflammatory response and associated airways function changes, such as the 
LAR and AHR. Interaction between cellular Ca2+ and Mg2+ may provide a 
mechanism for beneficial actions of inhaled MgSO4 against both the inflammation 
and bronchoconstriction in asthma (Tam et al., 2003). The anti-inflammatory 
actions of MgSO4 observed here suggest that its use in the treatment of asthma 
should be extended to more chronic administration than is currently 
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recommended. Although L-type calcium channel blockers such as nifedipine 
showed promise in early studies, this has not translated into therapeutic 
effectiveness in asthma (Fanta, 1985). If the same synergism exists between 
nifedipine and β-adrenoceptor agonists as seen here with MgSO4, then these 
studies open the possibility for effective combination therapy in asthma.  
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Figure Legends 
 
 
Fig. 1. Effects of MgSO4 and salbutamol on histamine-induced 
bronchoconstriction in conscious guinea-pigs. A. Inhibition of histamine-induced 
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bronchoconstriction following treatment with nebulised MgSO4 (62.5-250 mM) or 
vehicle (O). MgSO4 significantly inhibited the histamine response at 250mmol; 
**P<0.01, one-way ANOVA and Dunnett’s post hoc test. B. Inhibition of 
histamine-induced bronchoconstriction following treatment with nebulised 
salbutamol (0.035-0.1 mM) or vehicle (O). Histamine-induced 
bronchoconstriction was significantly inhibited by salbutamol at 0.07 and 0.1 mM; 
*P<0.05, **P<0.01, one-way ANOVA followed by post hoc Dunnett’s. C. Dose-
response curves for inhibition of histamine-induced bronchoconstriction by 
salbutamol () and MgSO4 () showing the IC50 values (mM) and the dose-ratio 
(R) at the IC50. D.  The individual and combined bronchoprotection by nebulised 
MgSO4 (62.5 mM) and salbutamol (0.035 mM) against histamine-induced 
bronchoconstriction. The combination of MgSO4 and salbutamol inhibited the 
histamine response to a greater extent than either drug alone; *P<0.05, one-way 
ANOVA followed by post hoc Tukeys. Responses are the mean n=6 % inhibition 
of the peak histamine response ± S.E.M. 
 
Fig. 2. Changes in airways function of conscious ovalbumin-sensitized guinea-
pigs following inhalation of ovalbumin (0.03% for 1 h). Guinea-pigs were treated 
with either saline control () or MgSO4 (, 250 mM) for 15 min before the 
ovalbumin challenge. Changes in sGaw are expressed as a percentage of the 
baseline (BL) immediately before ovalbumin exposure. Mean values (n=6) ± 
S.E.M. are shown including the mean peak fall in sGaw occurring between 9 and 
11 h. * Significant difference between the MgSO4- and saline-treated groups by Student’s unpaired t-test P<0.05. 
 
Fig. 3. Time courses for the changes in sGaw following exposure of conscious 
ovalbumin-sensitized guinea-pigs to nebulised histamine (0.3 mM, 2 min).  
Responses to histamine were obtained before (Pre-OVA, ) ovalbumin exposure 
(0.03% for 1 h) and at 24 h after OVA exposure (Post-OVA, ). A. Guinea-pigs 
received no treatment (control). B. Guinea-pigs received nebulised vehicle 
(saline) for 15 min before ovalbumin exposure. C. Guinea-pigs received 
nebulised MgSO4 (250 mM) for 15 min before ovalbumin exposure. Responses 
are the mean changes (n=6) in sGaw expressed as a % of the baseline value (BL) 
obtained before histamine exposure ± S.E.M. * Significantly different from the 
Pre-OVA value by Student’s paired t-test P<0.05. 
 
Fig. 4. Leukocyte numbers in bronchoalveolar lavage fluid removed from 
ovalbumin-sensitized guinea-pigs 24 h after ovalbumin (OVA, 0.03% for 1 h) 
challenge. Total cells, macrophages, eosinophils, lymphocytes and neutrophils 
are expressed as the mean ± S.E.M cell number (x106/ml n=6). Cells were 
obtained from guinea-pigs that were untreated (naïve) and from ovalbumin 
sensitized and challenged guinea-pigs that received no treatment (OVA), 
received saline (OVA + vehicle) or received MgSO4 (250 mM, for 15 min before 
OVA challenge) (OVA + MgSO4). * Significant difference between vehicle-treated 
and MgSO4-treated animals by Student’s unpaired t-test P<0.05. 
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Fig. 5. Leukocyte numbers in bronchoalveolar lavage fluid removed from non-
sensitised guinea-pigs 24 h after the second of two inhalation exposures to 
lipopolysaccharide 48 h apart (LPS, 30 g/ml for 1 h). Total cells, macrophages, 
eosinophils, lymphocytes and neutrophils are expressed as the mean ± S.E.M. 
cell number (x106/ml n=6). Cells were obtained from guinea-pigs that were 
untreated (naïve) and from LPS challenged guinea-pigs that received no 
treatment (LPS), received saline (LPS + saline) or received MgSO4 (250 mM, 15 
min) daily for 6 days 15 min before LPS challenge (LPS + MgSO4). *** 
Significantly different from saline-treated animals by Student’s unpaired t-test 
P<0.001. 
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